Decatur, GA, United States of America

Jing Shaw

This inventor holds 4 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2014-2024.

USPTO Granted Patents = 4 

% Patents Active = 100.0


 

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 23(Granted Patents)


Company Filing History:


Years Active: 2014-2024

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations of Inventor Jing Shaw

Introduction

Jing Shaw is a notable inventor based in Decatur, GA (US). He has made significant contributions to the field of pathogen research, holding a total of 4 patents. His work focuses on methods that enhance the understanding of pathogen behavior and their potential applications in immunogenic compositions.

Latest Patents

One of Jing Shaw's latest patents is titled "Modulation of replicative fitness by deoptimization of synonymous codons." This patent discloses methods for producing a pathogen with reduced replicative fitness. The methods involve deoptimizing one or more codons in a coding sequence, which ultimately reduces the replicative fitness of the pathogen. Additionally, the patent discusses the use of these attenuated pathogens as immunogenic compositions.

Career Highlights

Jing Shaw is affiliated with the United States of America, as represented by the Secretary, Department of Health and Human Services. His work has been instrumental in advancing the understanding of pathogen dynamics and their implications for public health.

Collaborations

Some of his notable coworkers include Cara Carthel Burns and Olen M Kew. Their collaborative efforts contribute to the innovative research being conducted in the field.

Conclusion

Jing Shaw's contributions to pathogen research through his patents highlight the importance of innovation in addressing health challenges. His work continues to pave the way for advancements in immunogenic applications.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…